title: Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients.
abstract: Serum soluble receptor for advanced glycation end product (sRAGE) may reflect the activity of the advanced glycation end product (AGE)-receptor for advanced glycation end product (RAGE) axis, which has been proposed as a potential mechanism linking hyperglycaemia to vascular complications in diabetes. We have investigated whether serum AGEs, sRAGE and pentosidine levels were increased and correlated with microvascular complications in type 2 diabetes mellitus (DM). We included 30 healthy control subjects, and 200 diabetic patients were divided into two subgroups: 100 patients with diabetic retinopathy and 100 patients with diabetic nephropathy. AGEs, sRAGE and pentosidine were measured in serum by enzyme-linked immunosorbent assay (ELISA). Serum AGEs, sRAGE and pentosidine levels were significantly increased in diabetic patients with retinopathy and in diabetic patients with nephropathy compared to control subjects (p < 0.001). Serum AGEs, sRAGE and pentosidine levels are positively associated with microvascular complications in type 2 DM. Multiple regression analysis reveals serum pentosidine as an independent determinant of the presence of diabetic retinopathy (p = 0.004) and the presence of hypertension (p = 0.018) and hyperlipidaemia (p = 0.036). Pentosidine levels may be a biomarker for microvascular complications in type 2 diabetic patients.
authors.affiliation: Higher Institute of Biotechnology, Monastir University, Monastir, Tunisia. mohsen.kerkeni@yahoo.fr
authors.forename: Mohsen
authors.initials: M
authors.lastname: Kerkeni
authors.forename: Amel
authors.initials: A
authors.lastname: Saïdi
authors.forename: Hassan
authors.initials: H
authors.lastname: Bouzidi
authors.forename: Ahmed
authors.initials: A
authors.lastname: Letaief
authors.forename: Salim
authors.initials: S
authors.lastname: Ben Yahia
authors.forename: Mohamed
authors.initials: M
authors.lastname: Hammami
mesh_terms: D000368:Aged; D001120:Arginine / Q000031:analogs & derivatives* / Q000097:blood; D015415:Biomarkers / Q000097:blood; D015331:Cohort Studies; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D003925:Diabetic Angiopathies / Q000097:blood* / Q000150:complications / Q000503:physiopathology; D003928:Diabetic Nephropathies / Q000097:blood / Q000150:complications / Q000503:physiopathology; D003930:Diabetic Retinopathy / Q000097:blood / Q000150:complications / Q000503:physiopathology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D017127:Glycation End Products, Advanced / Q000097:blood* / Q000737:chemistry; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications; D006973:Hypertension / Q000150:complications; D008239:Lysine / Q000031:analogs & derivatives* / Q000097:blood; D008297:Male; D055806:Microvessels / Q000503:physiopathology*; D008875:Middle Aged; D011446:Prospective Studies; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000097:blood* / Q000737:chemistry; D012720:Severity of Illness Index; D015854:Up-Regulation
chemical_list: D015415:Biomarkers; D017127:Glycation End Products, Advanced; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic; D001120:Arginine; C062187:pentosidine; D008239:Lysine